USFDA issues EIR for Zydus Lifesciences Ambernath facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-05-15 08:15 GMT | Update On 2025-05-15 08:15 GMT
Ahmedabad: Zydus Lifesciences has announced that the company has received the Establishment Inspection Report (EIR) report from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra.
This facility underwent an inspection from 10th to 14th February 2025, and had ended with NIL observations.
Read also: Zydus' Ambernath API Plant Clears USFDA Inspection with Zero Observations
The EIR report has classified it as No Action Indicated (NAI).
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.